Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma

Melanoma Research

Volumn 13, Issue 2, 2003, Pages 189-196

  Wolchok, Jedd D ^a   Williams, Linda ^a   Pinto, John T ^b   Fleisher, Martin ^a   Krown, Susan E ^a   Hwu, Wen Jen ^a   Livingston, Philip O ^a   Chang, Christine ^a   Chapman, Paul B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b AMERICAN HEALTH FOUNDATION   (United States)

Author keywords

Alkylating agent; Antioxidant; Carmustine; Glutathione; N acetylcysteine

Indexed keywords

ACETYLCYSTEINE; ALKYLATING AGENT; ANTIOXIDANT; CARMUSTINE; DEXAMETHASONE; GLUTATHIONE; GRANISETRON; ONDANSETRON; PARACETAMOL;

ANEMIA; ARTICLE; ASPIRATION PNEUMONIA; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG SAFETY; ELECTROLYTE DISTURBANCE; FEMALE; HEPATIC ENCEPHALOPATHY; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPOKALEMIA; LEUKOPENIA; LIVER TOXICITY; LUNG DISEASE; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; METASTASIS; MONONUCLEAR CELL; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; THROMBOCYTOPENIA; TUMOR RESISTANCE; VOMITING;

ACETAMINOPHEN; ACETYLCYSTEINE; ANALGESICS, NON-NARCOTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; CARMUSTINE; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FREE RADICAL SCAVENGERS; GLUTATHIONE; GLUTATHIONE REDUCTASE; HUMANS; LEUKOCYTES, MONONUCLEAR; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; NEOPLASM METASTASIS; SKIN NEOPLASMS; TIME FACTORS;

EID: 0037565704     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200304000-00013     Document Type: Article

References (29)

1. Houghton AN, Legha S, Bajorin DF. Chemotherapy for metastatic melanoma. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong S-J (editors), Cutaneous Melanoma. Philadelphia: JB Lippincott; 1992, pp. 499-508.
2. Sirott MN, Bajorin DF, Wong GYC, Tao Y, Chapman PB, Templeton MA, Houghton AN. Prognostic factors in patients with metastatic melanoma: a multivariate analysis. Cancer 1993; 72:3091-3098.
3. Kirkwood JM, Agarwala SS. Systemic cytotoxic and biologic therapy of melanoma. In: DeVita VTJ, Hellman S, Rosenberg SA (editors). Principles and Practices of Oncology. PPO Updates Volume 7; 8. Philadelphia: JB Lippincott, 1993.
4. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17:2745-2751.
5. Sertoli MR, Queirolo P, Bajetta E, DelVecchio M, Comella G, Barduagni L, et al. Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma). Melanoma Res 1999; 9:503-509.
6. Smit NP, Peters K, Menko W, Westerhof W, Pavel S, Riley PA. Cytotoxicity of a selected series of substituted phenols towards cultured melanoma cells. Melanoma Res 1992; 2:295-304.
7. Benathan M, Alvero-Jackson H, Mooy AM, Scaletta C, Frenk E. Relationship between melanogenesis, glutathione levels and melphalan toxicity in human melanoma cells. Melanoma Res 1992; 2:305-314.
8. Prezioso JA, FitzGerald GB, Wick MM. Melanoma cytotoxicity of buthionine sulfoximine (BSO) alone and in combination with 3,4-dihydroxybenzylamine and melphalan. J Invest Dermatol 1992; 99:289-293.
9. Arrick BA, Nathan CF. Inhibition of glutathione synthesis augments lysis of murine tumor cells by sulfhydryl-reactive antineoplastics. J Clin Invest 1983; 71:258-267.
10. Fruehauf JP, Yu IR, Pavich D, Buzaid AC. GSH depletion by BSO is cytotoxic in vitro for human melanoma and enhances BCNU activity. Proc Annu Meet Am Assoc Cancer Res 1994; 38:A2257.
11. Khil MS, Kim SH, Pinto JT, Kim JH. Ethacryinic acid: a novel radiation enhancer in human carcinoma cells. Int J Radiat Oncol Biol Phys 1996; 34:375-380.
12. Russo A, Mitchell JB. Potentiation and protection of doxorubicin cytotoxicity by cellular glutathione modulation. Cancer Treat Rev 1985; 69:1293-1296.
13. O'Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T, et al. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol 1996; 14:249-256.
14. Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, et al. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. J Clin Oncol 1994; 12:194-205.
15. Siemann DW. Modification of chemotherapy by nitroimidazoles. Int J Radiat Oncol Biol Phys 1984; 10:1585-1594.
16. Cohen MB, Duvel DL. Characterization of the inhibition of glutathione reductase and the recovery of enzyme activity in exponentially growing murine leukemia (L1210) cells treated with 1,3-bis(2-chloroethyl)-1-nitrosourea. Biochem Pharmacol 1988; 37:3317-3320.
17. Vanhoefer U, Yin MB, Harstrick A, Seeber S, Rustum YM. Carbamoylation of glutathione reductase by N,N-bis(2-chloroethyl)-N-nitrosourea associated with inhibition of multidrug resistance protein (MRP) function. Biochem Pharmacol 1997; 53:801-809.
18. Pinto JT, Qiao C, Xing J, Rivlin RS, Protomastro ML, Weissler ML, et al. Effects of garlic thioallyl derivatives on growth, glutathione concentration, and polyamine formation of human prostate carcinoma cells in culture. Am J Clin Nutr 1997; 66:398-405.
19. Lakritz J, Plopper CG, Buckpitt AR. Validated high-performance liquid chromatography-electrochemical method for determination of glutathione and glutathione disulfide in small tissue samples. Anal Biochem 1997; 247:63-68.
20. Kobrinsky NL, Hartfield D, Horner H, Maksymiuk A, Minuk GY, White DF, Feldstein TJ. Treatment of advanced malignancies with high-dose acetaminophen. Cancer Invest 1996; 14:202-210.
21. TR)-sulfoximine. Cancer Res 1989; 49:2327-2331.
22. Revesz L, Edgren MR, Wainson AA. Selective toxicity of buthionine sulfoximine (BSO) to melanoma cells in vitro and in vivo. Int J Radiat Oncol Biol Phys 1994; 29:403-406.
23. Applegate LA, Scaletta C, Labidi F, Vile GF, Frenk E. Susceptibility of human melanoma cells to oxidative stress including UVA radiation. Int J Cancer 1996; 67:430-434.
24. Morton RF, Creagan ET, Schaid DJ, Kardinal CG, McCormack GW, McHale MS, Wiesenfeld M. Phase II trial of recombinant leukocyte A interferon (IFN-alpha 2A) plus 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and the combination cimetidine with BCNU in patients with disseminated malignant melanoma. Am J Clin Oncol 1991; 14:152-155.
25. Luce JK. Chemotherapy of malignant melanoma. Cancer 1972; 30:1604-1615.
26. Jones AL, O'Brien ME, Lorentzos A, Viner C, Hanrahan A, Moore J, et al. A randomised phase II study of carmustine alone or in combination with tumour necrosis factor in patients with advanced melanoma. Cancer Chemother Pharmacol 1992; 30:73-76.
27. Clark SJ, Shojaee-Moradie F, Croos P, Seed PT, Umpleby AM, Wendon JA, Miell J. Temporal changes in insulin sensitivity following the development of acute liver failure secondary to acetaminophen. Hepatology 2001; 34:109-115.
28. Raucy JL, Curley G, Carpenter SP. Use of lymphocytes for assessing ethanol-mediated alterations in the expression of hepatic cytochrome P4502E1. Alcohol Clin Exp Res 1995; 19:1369-1375.
29. Benathan M, Virador V, Furumura M, Kobayashi N, Panizzon RG, Hearing VJ. Co-regulation of melanin precursors and tyrosinase in human pigment cells: roles of cysteine and glutathione. Cell Mol Biol (Noisy-le-grand) 1999; 45:981-990.